In higher-risk, statin-intolerant adults with diabetes, bempedoic acid reduced MACE at a median 3 y

Source CitationRay KK, Nicholls SJ, Li N, et al; CLEAR OUTCOMES Committees and Investigators. Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial. Lancet Diabetes Endocrinol. 2024;12:19-28. https://pubmed.ncbi.nlm.nih.gov/38061370/